physical health

Views & Analysis

Going beyond the pill is proving to be a win/win for patients and pharma alike – because improved outcomes are better for everyone.

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.